Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Edwards Lifesciences Corp Director's Dealing 2021

Oct 8, 2021

30042_dirs_2021-10-08_366b35bf-a008-409c-b5d5-1d2999a93e3c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-10-08

Reporting Person: BOBO DONALD E JR (CVP,Strategy/Corp Development)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-10-08 Common Stock M 11050.0000 $21.7600 Acquired 67449.3995 Direct
2021-10-08 Common Stock S 100.0000 $111.0550 Disposed 67349.3995 Direct
2021-10-08 Common Stock S 10950.0000 $110.4818 Disposed 56399.3995 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-10-08 Employee Stock Option (Right to Acquire) $21.7600 M 11050.0000 Disposed 2022-05-13 Common Stock (11050.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 38157.8315 Indirect
Common Stock 123820.0000 Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 1, 2021.

F2: This transaction was executed in multiple trades at prices ranging from $109.9850 to $110.9800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F3: Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.